<DOC>
	<DOCNO>NCT00942851</DOCNO>
	<brief_summary>Background : - Blepharospasm cause excessive contraction muscle close eye . It treat injection botulinum neurotoxin ( BoNT ) , work weaken muscle . - Acetyl Hexapeptide-8 ( AH-8 ) active ingredient number cosmetic cream use treat wrinkle , market trade name Argireline ( Copyright ) . Like BoNT , AH-8 work weaken muscle , available skin cream instead injection . AH-8 never use treat people blepharospasm . Objectives : - To determine AH-8 used part treatment regimen blepharospasm . Eligibility : - Individuals 18 year age old blepharospasm receive successful treatment botulinum toxin injection . Design : - Participants involve study maximum 7 month . - Patients complete physical neurological exam , ask question blepharospasm . Patients receive BoNT injection area muscle around eye dos effective previously . - After injection , patient receive container either active cream ( AH-8 ) cream without AH-8 , instruct apply . - Patients return 1 month first visit another neurologic exam question , ask side effect . Another supply cream give . - Five additional visit take place monthly basis , patient give additional supply cream need . Patients stop participate study require another BoNT injection blepharospasm . The study end 7 month .</brief_summary>
	<brief_title>A Study Acetyl Hexapeptide-8 ( AH8 ) Treatment Blepharospasm</brief_title>
	<detailed_description>OBJECTIVE : To study efficacy cutaneous application Acetyl Hexapeptide-8 ( AH8 ) therapy blepharospasm . STUDY POPULATION : 22 patient blepharospasm . DESIGN : This double blind , placebo-controlled trial . Patients receive treatment blepharospasm botulinum neurotoxin ( BoNT ) recruit . They receive either study substance placebo cream contain emulsion active substance , twice daily application eyelid begin day follow BoNT injection treatment . They continue apply cream record time condition worsen back baseline follow benefit injection , hypothesize cream application prolong time need next injection least 3 month . OUTCOME MEASURES : : Primary : time Jankovic Blepharospasm Rating Scale ( JBRS ) revert back baseline . Secondary : Change JBRS 6 month ; Change JBRS 7 month receive BoNT ; Change JBRS 3 month ; Change Blepharospasm Disability Scale 6 month</detailed_description>
	<mesh_term>Dystonia</mesh_term>
	<mesh_term>Dystonic Disorders</mesh_term>
	<mesh_term>Blepharospasm</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Age 18 year 2 . Diagnosis PB make Movement Disorders Neurologist 3 . Severity PB prompt need treatment determine patient subjective assessment . 4 . JBRS least 3 initial visit . 5 . BDS least 8 entry visit . 6 . At least three prior successful injectable BoNT treatment , stable interval injection 3 month ( ie duration response 3 month ) . EXCLUSION CRITERIA : 1 . Pregnant woman 2 . Blepharospasm associate different Neurologic condition , include limited generalyzed dystonia , parkinsonian syndrome , major brain structural abnormality , evidence Neurologic exam and/or review record 3 . Skin condition result loss integrity skin overlie OO potentially interfere cream absorption . 4 . Medical condition impair patient 's ability comply study protocol perform daily application cream instruct 5 . Abnormally long short response BoNT treatment past , ie duration PB relief BoNT great 4 month le 2 month . 6 . Allergy component study placebo cream . 7 . Known observed eye pathology .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Dystonia</keyword>
	<keyword>Blepharospasm</keyword>
	<keyword>Botulinum Toxin</keyword>
	<keyword>Treatment</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Focal Dystonia</keyword>
</DOC>